Heidelberg Pharma has patented a method for synthesizing amanitin derivatives with an amino group at position 6′ of the central tryptophan moiety. The patent also covers the use of these derivatives in conjugates for treating various cancers, including breast, pancreatic, and colorectal cancer, that are responsive to inhibition of mammalian RNA polymerase II. GlobalData’s report on Heidelberg Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Heidelberg Pharma AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Heidelberg Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Heidelberg Pharma's grant share as of April 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Amanitin derivative conjugates for treating cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Heidelberg Pharma AG

A recently granted patent (Publication Number: US11926631B2) discloses a method for treating cancer in patients by administering a conjugate containing an amanitin derivative with a 6'-amino-substituted tryptophan moiety, a target-binding moiety, and optionally a linker. The cancer types targeted by this method include breast cancer, pancreatic cancer, cholangiocarcinoma, colorectal cancer, prostate cancer, leukemia, and malignant lymphoma, all of which are responsive to the inhibition of mammalian RNA polymerase II.

The patent also covers a method of treating cancer by administering a pharmaceutical composition containing a conjugate with similar components as mentioned earlier. The cancer types eligible for treatment under this method are the same as the previous one, with a focus on cancers that respond to the inhibition of mammalian RNA polymerase II. The patent specifies the selection of amanitin derivatives, including S-desoxy-6'-amino-amanin, 6'-amino-amanin, S-desoxy-6'-amino-amaninamide, and 6'-amino-amaninamide, for effective cancer treatment in patients.

To know more about GlobalData’s detailed insights on Heidelberg Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies